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ABSTRACT: For effective clinical management of cystic fibrosis (CF) lung disease it is
important to closely monitor the start and progression of lung damage. The aim of this
study was to investigate the ability of high-resolution computed tomography (HRCT)
scoring systems and pulmonary function tests (PFT) to detect changes in lung disease.
CF children (n=48) had two HRCT scans in combination with two PFT 2 yrs apart.
Their scans were scored using five scoring systems (Castile, Brody, Helbich,
Santamaria and Bhalla). "Sensitivity" was defined as the ability to detect disease
progression.
In this group of children, HRCT scores worsened. PFT remained unchanged or
improved. Of the HRCT parameters, mucous plugging and the severity, extent and
peripheral extension of bronchiectasis worsened significantly. Relationships between
changes in HRCT scores and PFT were weak. Substantial structural lung damage was
evident in some children who had normal lung function.
These data show that high-resolution computed tomography is more sensitive than
pulmonary function tests in the detection of early and progressive lung disease, and
suggest that high-resolution computed tomography may be useful in the follow up of
cystic fibrosis children and as an outcome measure in studies that aim to reduce lung
damage.
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In cystic fibrosis (CF), chronic bacterial infection leads to
progressive structural lung damage and to pulmonary dys-
function. It is generally accepted that early and aggressive
therapy could delay the progression of lung disease. To
evaluate the efficacy of such treatment it is important to
monitor the progression of lung damage closely. Pulmonary
function tests (PFT) are considered the gold standard for
the monitoring of lung disease in children of aged o6 yrs.
However, since lung function is only indirectly related to lung
structure, it is likely that high-resolution computed tomo-
graphy (HRCT) is more sensitive than PFT in the detection of
structural changes compared with PFT [1]. Some CF centres
have adapted periodic HRCT on a routine basis to evaluate
the progression of CF lung disease in combination with
PFT. However, it is unclear what method should be used
to analyse the HRCT and whether HRCT is more sensitive in
detecting pulmonary disease progression in CF. It could be
that PFT and HRCT provide complementary information
and should be performed in parallel to assess progression. The
aim of this study was to investigate the sensitivity of five
different HRCT-scoring systems and PFT to detect changes
in CF structural lung disease over time.
Methods
Study population
Since 1996, Sophia Children9s Hospital (Rotterdam, The
Netherlands), a tertiary academic hospital has monitored CF
patients using annual PFT and biennial HRCT scans. All
children with CF who had two HRCT scans (HRCT1 and
HRCT2) in combination with two routine PFT (PFT1 and
PFT2) were selected for this follow-up study (n=48). CF was
diagnosed by a positive sweat test and/or genotyping for
known CF mutations and/or an abnormal potential difference
measured across the nasal mucosa. The ethical review board
of the hospital approved the study.
Lung structure
All HRCT scans were acquired using a GE Prospeed
SX scanner (General Electric Medical Systems, Milwaukee,
WI, USA). During the scanning procedure, children were
not sedated, they were scanned in the supine position, and
Eur Respir J 2004; 23: 93–97
DOI: 10.1183/09031936.03.00006603
Printed in UK – all rights reserved
Copyright #ERS Journals Ltd 2004
European Respiratory Journal
ISSN 0903-1936
instructed to take a deep breath and hold it for o5 s. A
complete HRCT series contained y25 1-mm thick slices at
10-mm intervals from lung apex to lung base. Scanning
parameters were 120 kV, 160 mA (v9 yrs of age 120 mA), 1-s
scanning time and a field of view of 350 mm (v9 yrs of age
250 mm). Scans were reconstructed with a detail recon-
struction algorithm (General Electric Medical Systems) and
printed using window width -600 Hounsfield units (HU) and
window level 1,500 HU. All HRCT scans were scored in
random order by an experienced single observer blinded as to
the date of the scan, patient identification and the PFT. Five
different HRCT-scoring systems were used: CASTILE et al. [2],
BRODY et al. [3], HELBICH et al. [4], SANTAMARIA et al. [5], and
BHALLA et al. [6]. In a previous study, in which the observer of
this study participated, these five scoring systems were shown
to be reliable between and within observers [7]. All slices were
used to score the lung lobes and the lingula [2, 3] or the
bronchopulmonary segments of the lung [4–6]. The systems
score bronchiectasis, bronchial wall thickening, mucous plug-
ging, atelectasis, bulla, cysts, consolidation, acinar nodules,
septal thickening and/or air trapping in a semiquantitative
fashion. A score of zero means "no abnormalities" in each
system. Maximal scores are 92, 100, 27, 29 and 25 for Castile,
Brody, Helbich, Santamaria and Bhalla scores, respectively.
Lung function
All PFT were done within 1 month of the HRCT scanning
using a Ja¨ger diagnostic system (MasterLab, Ja¨ger, Germany).
Most scans were performed on the same day (71 of 96 scans)
as the PFT. All HRCT scans were done as part of a routine
check-up and thus patients were scanned in a relatively stable
condition and not during an exacerbation. PFT results were
expressed as percentage of predicted values: forced expiratory
volume in one second (FEV1) [8], forced vital capacity (FVC)
[8], forced expiratory flow between 25% and 75% of expira-
tory vital capacity (FEF25–75%) [9], airway resistance (Raw)
[10], residual volume (RV) [10], total lung capacity (TLC) and
RV/TLC [10]. The ratio FEV1/FVC and the ratio RV/TLC
were expressed as a percentage (FEV1/FVC % and RV/TLC
%). Twelve patients were younger than patients studied by
WANG et al. [9] in the development of the prediction equation
for FEF25–75%. Body plethysmography (TLC, RV and Raw)
was performed in 33 of the 48 children. Normal lung function
was defined as a FEV1 ofw85% predicted.
Lung structure and lung function over time
Data obtained at the first evaluation are reported as
HRCT1 and PFT1, and data obtained at the second
evaluation are reported as HRCT2 and PFT2. DHRCT is
the annual change for a scoring system ((HRCT2-HRCT1)/
time interval). To compare the annual changes of the five
HRCT-scoring systems, DHRCT was also expressed as a
percentage of the maximal obtainable HRCT score for that
system. DPFT is the annual change expressed as % pred for a
lung function parameter ((PFT2-PFT1)/time interval). A
positive value for DHRCT indicates an increase of structural
abnormalities and for DPFT an improvement in lung
function. DHRCT and DPFT were evaluated for the whole
group and separately for children younger than and older
than 10 yrs of age. DHRCT and DPFT were also evaluated as
a function of age and baseline disease severity (HRCT1 and
FEV1 % pred).
Statistical analysis
For the purpose of this article, the term sensitivity is not
used in the statistical sense but rather as a measure of the
techniques9 ability to track pulmonary disease progression in
CF. It was assumed that, on average, CF lung disease would
be progressive over 2 yrs and that the method that detected
the largest change was most "sensitive". The relationships
between HRCT1 and PFT1, HRCT2 and PFT2, between
DHRCT and DPFT and between DHRCT, DPFT, HRCT1,
PFT1 and age were evaluated using the Spearman correlation
coefficient. t-tests (unpaired) were performed for DHRCT and
DPFT to determine whether HRCT and/or PFT changed
significantly in the whole group and for children below
and above 10 yrs of age. Wilcoxon-signed ranks tests were
used to determine which of the HRCT abnormalities changed
significantly. Statistical significance was set at a p-value of
v0.05. Data are presented as mean¡SD and range.
Results
Study population
Characteristics of the 48 children (28 male) are shown in
table 1. At HRCT1, 15 children had normal lung function
(31%). HRCT scores were 13.7¡8.7, 8.1¡6.8, 6.1¡2.9,
6.4¡3.2 and 6.1¡2.9 for Castile, Brody, Helbich, Santamaria
and Bhalla, respectively.
Lung structure and lung function over time
All HRCT scores worsened significantly. The mean changes
for the whole group expressed as a percentage of the maximal
scores were 2.6, 2.2, 3.3, 3.1 and 3.5% per year for Castile,
Brody, Helbich, Santamaria, and Bhalla, respectively. Spiro-
metric parameters (DFEV1, DFVC, DFEF25–75% and DFEV1/
FVC) did not change significantly. RV % pred, RV/TLC %
and RV/TLC % pred decreased by 8.9% (p=0.004), 2.4%
(p=0.0005) and 0.66% (pv0.0001) per year, respectively. Raw
and TLC did not change significantly. The subgroup analysis
of children below and above 10 yrs of age showed the same
results, with the exception that RV % pred remained
unchanged in the children w10 yrs of age. DHRCT and
DPFT did not differ as a function of baseline disease severity
or age, with the exception of significant relationships between
age and DRV % pred (R=0.53, p=0.001) and between age and
DRV/TLC % (R=0.46, p=0.008).
Of the HRCT scan parameters only mucous plugging
(p=0.001) and the severity (p=0.005), extent (pv0.0001) and
peripheral extension (p=0.02) of bronchiectasis worsened
significantly. Of the 48 patients, the severity of bronchiectasis
increased in 15, the score for the extent of bronchiectasis
increased in 19 and the score for the peripheral extension of
bronchiectasis increased in eight. In only three patients there
was a reduction of the severity of bronchiectasis (in all three
cases, the airway lumen diameter changed from y2–3-times
vessel diameter to y1–2-times vessel diameter). One patient
showed a reduction in the peripheral extension score.
Correlation between lung structure and lung function
Cross-sectional data showed a significant correlation
between HRCT1 and first FEV1 (Rv-0.49, pv0.0001), and
between HRCT2 and second FEV1 (Rv-0.58, pv0.0001).
Longitudinal data showed significant but weak correlation
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between DPFT and DHRCT: DFEV1/FVC versus DSantamaria
(R=-0.31, p=0.04), DRaw versus DHelbich (R=0.37, p=0.04),
DRaw versus DSantamaria (R=0.38, p=0.03), DRV versus
DBrody (R=0.35, p=0.04), DRV/TLC versus DBrody (R=0.38,
p=0.03), and DRV/TLC versus DHelbich (R=0.41, p=0.02).
The relationship between DFEV1/FVC and DSantamaria is
shown in figure 1.
Discussion
In this study, the ability of five different HRCT-scoring
systems and pulmonary function tests were compared to
detect and monitor progression of lung damage in 48 children
with CF.
The most striking finding of this study is that structural
abnormalities as scored on HRCT scans increased signifi-
cantly, independently of the scoring system used, while lung
function parameters remained unchanged or even improved.
This shows that HRCT was more sensitive than PFT in
monitoring CF lung disease under the assumption that CF
lung disease is progressive. In addition, the authors showed
that it was predominantly the severity, extent and peripheral
extension of bronchiectasis that worsened significantly. The
bronchiectasis most likely represents irreversible structural
damage. The irreversibility of bronchiectasis is supported by
the fact that none of the patients who had bronchiectasis on
HRCT1 were without bronchiectasis on HRCT2.
There are a number of possibilities why the structural
abnormalities on HRCT were not reflected by the PFT.
Firstly, the signal-to-noise ratio for PFT is likely to be less
than that of HRCT since PFT depend more on patient
cooperation than HRCT, especially for the younger children,
and since PFT are more difficult to perform than a breath-
hold on the HRCT table. Indeed, the HRCT can be scored
even when there is minor motion artefact or some variation in
inflation level. Furthermore, the results of PFT are expressed
as % pred with reference to a large population sample and this
can introduce variability related to the pubertal growth spurt
[11]. In addition, HRCT can detect local abnormalities such
as small areas of atelectasis and bronchiectasis that may be
functionally insignificant. PFT provide a global estimate of
the lung integrity [1]. In this study RV % pred improved for
the whole group, but remained unchanged for the children
w10 yrs of age. The improvement in RV may, therefore, be a
reflection of patient effort. For the young children it is more
difficult to reach RV during expiration. However, the RV/
TLC % and RV/TLC % pred improved slightly in the children
w10 yrs of age. This suggests that the improvement in RV/
TLC % pred is only partially caused by an effect of age. The
second important finding of this study is that the structural
damage was irreversible in most patients irrespective of their
change in PFT. In many patients the change in HRCT was
dissociated from changes in PFT. Approximately one-half of
the patients who had improved lung function had progressive
structural lung disease.
The third important finding is that substantial structural
lung damage was present on HRCT scans even in children
who had lung function within the normal range. This sup-
ports the conclusions of earlier studies that conventional
PFT are relatively insensitive to detect the onset and early
progression of lung disease in CF [1, 7, 12]. These results
indicate that the current monitoring strategy using PFT may
fail to detect disease progression and suggest that studies
Table 1. – Patient characteristics
First HRCT Second HRCT Mean annual change
Age yrs 11.05¡3.30 13.04¡3.30 Interval 1.99
Body height m 1.37¡0.21 1.47¡0.20 0.047*
Body weight kg 32.5¡12.1 38.6¡13.9 3.46*
FEV1 % pred 74.3¡18.2 76.0¡21.0 1.24
FVC % pred 85.5¡15.7 85.1¡16.2 -0.11
FEF25–75% pred 58.8¡31.2 59.9¡32.0 -1.30
FEV1/FVC % 75.4¡10.6 77.6¡9.8 0.39
Raw % pred 136.1¡61.8 143.4¡76.0 0.10
RV % pred 136.6¡42.1 129.9¡40.2 -8.49*
TLC % pred 98.0¡13.2 96.8¡11.2 -1.06
RV/TLC % 33.2¡9.4 31.6¡9.7 -2.11*
Castile score [2] 17.7¡9.7 22.4¡11.4 2.39*
Brody score [3] 12.1¡8.7 16.3¡10.2 2.21*
Helbich score [4] 8.4¡3.7 10.1¡3.8 0.88*
Santamaria score [5] 8.9¡4.0 10.7¡4.1 0.91*
Bhalla score [6] 8.2¡3.4 10.0¡3.6 0.87*
Data are presented as mean¡SD. HRCT: high-resolution computed tomography; FEV1: forced expiratory volume in one second; % pred: %
predicted; FVC: forced vital capacity; FEF25–75%: forced mid-expiratory flow; Raw: airway resistance; RV: residual volume; TLC: total lung
capacity. *: pv0.05 in 1 yr with the one-sample t–test (unpaired).
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Fig. 1. – The weak correlation (R=-0.31, p=0.04) between changes in
lung function (forced expiratory volume in one second (FEV1)/forced
vital capacity (FVC)) over a 1-yr period and structural changes on
high-resolution computed tomography (HRCT; Santamaria score) is
shown. Patients with improved lung function have a change in FEV1/
FVC above 0, and patients with progressive structural lung damage
have a Santamaria score above 0.
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using PFT to monitor treatment response may underestimate
treatment effects. Therefore, it is possible that because of
flawed outcome measures, the optimal treatment regime to
minimise the progression of structural lung damage in CF
patients is as yet unknown.
In this study, the HRCT features that changed most over
the 2-yr observation period were the severity score for
bronchiectasis and mucous plugging. Selective scoring of
these parameters, instead of the full range of parameters
included in the currently used complex scoring systems, may
be more efficient and reproducible. A simplified scoring
system may prove to be adequate for patient management and
therapeutic trials. Clearly, such a system should be tested in
further studies against the complex scoring systems to test this
hypothesis. Monitoring CF patients using HRCT carries
potential risk due to the associated radiation exposure. Since
the probability of cancer induction from ionising radiation is
highest in the paediatric age group [13] and increases with
each successive scan, the proposal to employ serial HRCT
scans must be balanced against the potential radiation risk.
Further research to determine the optimal scan parameters
and frequency of HRCT scans for CF monitoring is required.
a)
c) d)
b)
Fig. 2. – Patient with cystic fibrosis with improvement of lung function but detoriation of lung structure. The top panels (a and b) show high-
resolution computed tomography (HRCT) scan 1 in a patient of 10 yrs of age. Lung function (% predicted) is as follows: forced expiratory
volume in one second (FEV1) of 86, forced vital capacity (FVC) of 93, forced mid-expiratory flow (FEF25–75%) of 80, and FEV1/FVC of 80.
HRCT scores are: Castile 17, Brody 16, Helbich 9, Santamaria 10, and Bhalla 9. The lower panels (c and d) show HRCT2 at 13 yrs of age.
Lung function (% pred) is: FEV1 96, FVC 91, FEF25–75% 105, and FEV1/FVC 90. HRCT scores are: Castile 22, Brody 17, Helbich 12,
Santamaria 13, and Bhalla 12.
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This study has some limitations. First, only one observer
did the scoring. However, in a previous study, in which this
observer participated, it was shown that the within- and
between-observer variability for the five scoring systems was
good [7]. Secondly, clinical outcomes were not measured in
these patients and thus it cannot be assessed whether the
worsening on HRCT scans affected the clinical management
of the patients. However, a case scenario (fig. 2) illustrates
how CT scoring could be used in a clinical setting. In this
patient more aggressive therapy may have affected disease
progression if it had been detected earlier. Larger prospective
clinical studies in which CT scans are used in clinical decision
making are required to test the importance of this conjecture.
To the best of the authors9 knowledge, this is the first study
that shows that HRCT can reveal progressive, irreversible
structural damage in the lungs of cystic fibrosis patients over a
2-yr period; changes that are not associated with deterioration
in lung function. Since the evolution of lung function over
time may be dissociated from changes in the lung structure it
may be advantageous to include high-resolution computed
tomography in the standard follow-up of cystic fibrosis
patients. Furthermore, these data support the use of high-
resolution computed tomography as a measurement tool in
therapeutic trials for computed tomography patients, where
the outcome measure is a slowing of progression of lung
disease. Conversely, high-resolution computed tomography
involves significant radiation exposure and in this era of
prolonged patient survival in cystic fibrosis, the risk-benefit
ratio for routine high-resolution computed tomography
assessment needs to be more fully explored.
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